03.05.2020, 4506 Zeichen

Marinomed: Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, receives funding from the Austrian Research Promotion Agency (FFG) for the development of a SARS-CoV-2 therapy based on Carragelose®. The aim of the project is to clinically test an inhalation solution with Carragelose® as an acute treatment for viral pneumonia caused by SARS-CoV-2 or other respiratory viruses. The current project is funded by the FFG as part of the "Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2". The planned project volume is above Euro 4 mn, the maximum funding share is 45%. "A causal therapy directly in the lungs can shorten the duration of the disease and thus hospitalization for patients suffering from viral pneumonia, reduce the number of patients in intensive care and thus bring enormous benefits for patients and the health system," explains Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed. The patented Carragelose® developed by Marinomed is one of the very few active ingredients with clinical data from patients who have been infected with previously circulating coronaviruses. In 2014, an analysis of coronavirus infected patients showed that the duration of disease was reduced by more than 3 days in the Carragelose® treated group when compared to patients treated with placebo. Marinomed CSO Eva Prieschl-Grassauer: “We can now capitalize on this strong basis. Due to the broad effectiveness of Carragelose®, we are confident that we can also achieve good results with the current pandemic coronavirus.” Within a year, data should be available clarifing whether the Carragelose®inhalation solution is safe and its use in patients is a health improvement compared to a placebo. In the current project, the tolerance of the Carragelose® inhalation solution will be evaluated first in healthy volunteers. Subsequently a proof of concept study in patients with viral pneumonia will be conducted at the Medical University of Vienna. In parallel, existing data on the effectiveness of Carragelose® serve as basis for in-vitro tests that will be carried out together with the Medical University of Vienna in order to establish safety and effectiveness.
Marinomed Biotech: weekly performance: 3.17%

Strabag: Construction companies züblin and Strabag have acquired a new project in Germany. Working under a consortium arrangement, the two companies will build the extended shell of the southern section of the FAIR particle accelerator facility in Darmstadt, Germany. When it is completed, the Facility for Antiproton and Ion Research will be the world’s only particle accelerator facility for cutting-edge research into the evolution of the universe and the structure of matter. FAIR will be able to produce matter in the laboratory that otherwise only occurs in the depths of space. The contract for the extended shell of the southern section of the facility has a value of Euro 220 mn for Züblin and Strabag. Construction is scheduled to start in June 2020 with completion in summer 2023.
Strabag: weekly performance: 0.59%

A1 Telekom Austria: A1 Telekom Austria Group total revenues in the first quarter increased by 3.4 % to Euro 1,126.0 mn, with growth in Bulgaria, Belarus and Serbia and stable total revenues in Austria. Group EBITDA excluding restructuring charges increased slightly by 0.4% to Euro 396.6 mn (reported:+1.7%), driven by higher service revenues outweighing higher bad debt expense following higher expected lifetime credit loss of accounts receivables. “Due to the uncertain duration of the crisis, the further effects are not yet foreseeable and are quite diverse,” said Chief Executive Thomas Arnoldner. While an increased demand for bandwidth, home office solutions or digitization projects was positive, international travel restrictions had a negative impact on roaming revenues.
Telekom Austria: weekly performance: 3.55%

Palfinger: Lifting solutions company Palfinger has secured two important orders in India and Thailand: The Indian government orders over 600 cranes from Palfinger Cranes India Pvt Ltd, a subsidiary of Palfinger AG.  In Thailand, the Provincial Electricity Authority (PEA) has now commissioned a total of 301 equipment units from two Palfinger partners. Over the next ten months, Palfinger will assemble 211 aerial work platforms and 90 loading cranes and deliver them to the EPA.
Palfinger: weekly performance: 9.50%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (28/04/2020)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #788: Pierer Mobility am Geburtstag des Namensgebers mächtig im Plus, Yvonne de Bark lernt mir was

Bildnachweis

Aktien auf dem Radar:voestalpine, Pierer Mobility, Warimpex, Addiko Bank, CA Immo, Immofinanz, Verbund, ATX, ATX Prime, ATX TR, Bawag, Andritz, Österreichische Post, AT&S, Cleen Energy, Frauenthal, Kostad, Oberbank AG Stamm, Kapsch TrafficCom, DO&CO, Agrana, Amag, Erste Group, EVN, Flughafen Wien, OMV, Palfinger, RHI Magnesita, Semperit, S Immo, Telekom Austria.

---